Search Results

November 3, 2017

INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Medical technologies

January 11, 2016

FDA Approves Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring System For Use in Children

Insulin Pump System Offers Children Ages Two and Older an Integrated Solution for Diabetes Management

Innovative Medicine

November 15, 2016

Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking Remicade® (Infliximab) Compared To Ct-P13 (Infliximab Biosimilar)

Studies Presented at the 2016 ACR/ARHP Annual Meeting Reveal Higher Discontinuation Rates in Patients Newly Beginning or Switching to Treatment with CT-P13

Corporate

November 12, 2012

Johnson & Johnson Family of Diabetes Companies Provides Diabetes Supplies to Children in Developing Countries

LifeScan, Inc. supplies one million test strips and encourages support for International Diabetes Federation’s Life for a Child program

Innovative Medicine

June 12, 2017

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program

Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions

Innovative Medicine

June 13, 2016

New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management

Combination of Canagliflozin and Phentermine Demonstrates Improvements in Weight Management in Overweight or Obese Patients without T2DM

Innovative Medicine

August 8, 2014

U.S. FDA Approves INVOKAMET™ (canagliflozin/metformin HCl) for the Treatment of Adults with Type 2 Diabetes

In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone

Innovative Medicine

October 11, 2018

JANSSEN TO HIGHLIGHT DATA FROM BROAD RHEUMATOLOGY PORTFOLIO AT THE 2018 ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY

Corporate

July 9, 2015

Phase 2B Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis

Guselkumab, an anti-interleukin-23 monoclonal antibody, showed improvements in primary and secondary endpoints compared with placebo and active comparator adalimumab, an anti-tumor necrosis factor-alpha agent

Innovative Medicine

June 6, 2016

Janssen Expands Body of Evidence for INVOKANA® (canagliflozin) with 18 New Data Presentations at American Diabetes Association’s 76th Scientific Sessions®

Comparative Analyses with DPP-4 Inhibitors, Including Sitagliptin, and Findings on Use in Weight Management and Type 1 Diabetes Underscore Janssen Commitment to Improving Diabetes Management

Search Results

No Results

Recently Viewed

Search Results